Hoff AC. Abstract 548. Presented at: Digestive Disease Week; May 21-24, 2021; Virtual.
Hoff’s disclosures have been unavailable on the time of press..
Using Ozempic together with endoscopic sleeve gastrectomy resulted in larger weight reduction than the process alone, in accordance with a presentation at Digestive Diseases Week.
“A minimally invasive process often called endoscopic sleeve gastroplasty, or ESG, is offered to many patients with obesity who wish to forego surgery for weight loss and who aren’t candidates for procedures akin to laparoscopic sleeve gastroplasty,” Ana C. Hoff, MD, mentioned throughout a press convention previous to DDW. “However, ESG has not produced the identical weight reduction outcomes as bariatric surgical procedure.”
In the double-blind research, 61 sufferers underwent ESG. Twenty-nine of them acquired Ozempic (semaglutide, Novo Nordisk) beginning 1 month post-procedure whereas one other 29 acquired a placebo administered with comparable injector pens as these used with semaglutide. Three members have been misplaced to follow-up.
In the semaglutide group, sufferers misplaced a mean of 26.7% of their complete physique weight and 86.3% of their extra weight. In the placebo group, sufferers misplaced 19.6% of complete physique weight on common and 60.4% of their extra weight. Hoff additionally famous that HbA1c was higher managed within the semaglutide group with their ranges falling by 0.95 whereas the placebo group noticed a lower of 0.61.
Hoff famous that the members’ diabetes standing didn’t affect the outcomes.
“While bariatric surgery remains the gold standard for vital sustained weight reduction, fewer than 2% of eligible sufferers pursue this feature. As the worldwide weight problems fee continues to climb, so do the variety of folks looking for price efficient various strategies to surgical procedure to deal with their situation,” Hoff mentioned. “These wonderful outcomes are significantly thrilling as a result of ESG can be performed at an earlier stage of the disease and a decrease BMI which means extra sufferers can get the therapy earlier than their illness is progressing.”